Lymphomas and Chronic Lymphocytic Leukemia

Expert faculty review and share their insights and perspectives on key findings in lymphomas and CLL presented at the 2021 ASH Annual Meeting.

Share

Program Content

Activities

  • Lymphoma/CLL Highlights: ASH 2021
    Key Studies in Lymphomas and CLL: Independent Conference Coverage of ASH 2021
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 10, 2022

    Expires: May 09, 2023

Activities

Mosunetuzumab in R/R FL
Mosunetuzumab, a CD20 x CD3 Bispecific Antibody, in R/R Follicular Lymphoma With ≥2 Previous Therapies: Pivotal Phase II Trial Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2021

Expires: December 21, 2022

ELARA High-Risk RR FL
Phase II ELARA: Extended Follow-up and Subgroup Analysis of Tisagenlecleucel in High-Risk R/R Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

ZUMA-7
Primary Analysis of ZUMA-7: Randomized Phase III Trial of 2L Axicabtagene Ciloleucel vs Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

Valemetostat for R/R ATL
Pivotal Phase II Trial of Valemetostat, an EZH1/EZH2 Inhibitor, in Patients With R/R Adult T-Cell Leukemia/Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

ELEVATE-RR AEs
ELEVATE-RR: Characterization of BTKi-Related AEs in Acalabrutinib vs Ibrutinib in Previously Treated CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

CITADEL-205: Parsaclisib in R/R MCL
CITADEL-205: Phase II Study of Parsaclisib in Patients With BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

MK-1026 in CLL/SLL
Phase II Study of Novel BTK Inhibitor MK-1026 in Patients With R/R CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

ASCEND 3-Yr Update
3-Yr Follow-up of ASCEND Phase III Trial: Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab in R/R CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

SEQUOIA: zanubrutinib in CLL/SLL
Phase III SEQUOIA Trial of Zanubrutinib vs Bendamustine and Rituximab in Previously Untreated CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

MRD Surveillance in DLBCL
Prospective Study Evaluating MRD and CT Imaging Surveillance Following First-line Treatment in Patients With DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

Alliance 051701
Alliance 051701: Randomized Phase II/III Trial of DA-EPOCH-R ± Venetoclax in Patients With Previously Untreated Double-Hit Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

CAPTIVATE MRD Cohort 2-Yr Update
CAPTIVATE MRD Cohort: 2-Yr Postrandomization Efficacy and Safety With First-Line Ibrutinib + Venetoclax in CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

GLOW: Ibr + Ven and MRD
GLOW: MRD Outcomes After First-line Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Older/Unfit Patients With CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2021

Expires: December 11, 2022

Parsaclisib in R/R FL
CITADEL-203 Phase II Study of the PI3Kδ Inhibitor Parsaclisib in Patients With Relapsed/Refractory Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

TRANSFORM: Liso-Cel in LBCL
TRANSFORM: Lisocabtagene Maraleucel vs Salvage Chemotherapy Followed by ASCT as Second-Line Treatment in Relapsed/Refractory Large B-Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

POLARIX: Polatuzumab vedotin
POLARIX Trial of Polatuzumab Vedotin + R-CHP VS R-CHOP in Patients With Previously Untreated DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

BELINDA: Tisagenlecleucel in R/R NHL
Phase III BELINDA Trial of Tisagenlecleucel vs Standard of Care as Second-line Treatment for R/R Aggressive B-Cell Non-Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

Faculty

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation